Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 5,388 matching trials from the live ClinicalTrials.gov search.
Filters: Tucson, Arizona Clear all
Completed Phase 4 Interventional Results available

A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure

NCT00791258
View directory record Official record
Conditions
Hypertension
Interventions
amlodipine and olmesartan medoxomil tablets, hydrochlorothiazide tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
72
States / cities
Birmingham, Alabama • Green Valley, Arizona • Mesa, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Vitamin D Levels in the Skin of Healthy Subjects After Oral Supplementation

NCT01447355
View directory record Official record
Conditions
Healthy, no Evidence of Disease, Skin Cancer
Interventions
cholecalciferol
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

NCT04048135
View directory record Official record
Conditions
NASH
Interventions
Pegozafermin, Placebo
Drug · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

NCT00810693
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
18
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 25, 2026, 8:53 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

NCT05232916
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, GLSI-100
Biological
Lead sponsor
Greenwich LifeSciences, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
51
States / cities
Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Not applicable Interventional

Mechanisms of Change in Cognitive Behavioral Therapy for Insomnia (CBTi)

NCT05226585
View directory record Official record
Conditions
Sleep Initiation and Maintenance Disorders
Interventions
In-Person Cognitive Behavioral Therapy for Insomnia, Telehealth Cognitive Behavioral Therapy for Insomnia, Internet Cognitive Behavioral Therapy for Insomnia
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
50 Years to 65 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

BI 671800 ED in Steroid-naive Asthmatic Patients

NCT01092143
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 4 Interventional

GSK BHR Study (Sont)

NCT00920543
View directory record Official record
Conditions
Asthma
Interventions
Placebo, FP 100mcg, FP 500mcg, FP 250mcg, FSC 100/50mcg, FSC 250/50mcg, FSC 500/50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2016 · Synced Oct 25, 2026, 8:53 AM EDT
Not listed Phase 3 Interventional

A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration

NCT00454389
View directory record Official record
Conditions
Macular Degeneration
Interventions
Epi-Rad90™ Ophthalmic System, ranibizumab
Device · Drug
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 25, 2026, 8:53 AM EDT
Completed No phase listed Observational

LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices

NCT02091011
View directory record Official record
Conditions
Implantable Cardioverter Defibrillators, CRT-D Cardiac Resynchronization Therapy Defibrillator
Interventions
Not listed
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
Not listed
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
51
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

DHEA Against Vaginal Atrophy - Safety Study of 12 Months

NCT01256671
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
31
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects

NCT00699998
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Clopidogrel, Prasugrel, Commercially-available Aspirin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
9,326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
165
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated May 7, 2013 · Synced Oct 25, 2026, 8:53 AM EDT
Recruiting Phase 1 Interventional

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

NCT04729114
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer
Interventions
PRL-02 injection, prednisone, dexamethasone, enzalutamide
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
24
States / cities
Tucson, Arizona • Anaheim, California • Santa Rosa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 25, 2026, 8:53 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

NCT06974084
View directory record Official record
Conditions
Long COVID
Interventions
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
Drug
Lead sponsor
HealthBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults With Generalized Myasthenia Gravis

NCT03772587
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
M281, Placebo
Drug · Other
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 25, 2026, 8:53 AM EDT
Terminated Phase 2 Interventional Results available

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

NCT01995058
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
Interventions
cabozantinib, abiraterone, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
20
States / cities
Scottsdale, Arizona • Sedona, Arizona • Tucson, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause

NCT04003155
View directory record Official record
Conditions
Hot Flashes
Interventions
fezolinetant, placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
72
States / cities
Andalusia, Alabama • Birmingham, Alabama • Ensley, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.

NCT01272635
View directory record Official record
Conditions
Asthma, Wheezing
Interventions
Azithromycin, Prednisolone, Placebo Azithromycin, Placebo Prednisolone
Drug · Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Months to 71 Months
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
16
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps

NCT05274750
View directory record Official record
Conditions
Nasal Polyps
Interventions
Depemokimab (GSK3511294), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
26
States / cities
Tucson, Arizona • Buena Park, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 25, 2026, 8:53 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

NCT07035093
View directory record Official record
Conditions
Obesity, Overweight, Chronic Low Back Pain (CLBP)
Interventions
Retatrutide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
25
States / cities
Chandler, Arizona • Tucson, Arizona • Fountain Valley, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 8:53 AM EDT
Terminated No phase listed Observational

Long-Term Follow-up Study of Patients Who Received PB127 Ultrasound Imaging Agent

NCT00584714
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Point Biomedical
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
39
States / cities
Tucson, Arizona • Burlingame, California • Long Beach, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2008 · Synced Oct 25, 2026, 8:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

NCT04939428
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
59
States / cities
Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 25, 2026, 8:53 AM EDT
Not listed Phase 3 Interventional

Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization

NCT00438867
View directory record Official record
Conditions
Angina Pectoris
Interventions
Ad5FGF-4, Placebo
Genetic
Lead sponsor
Cardium Therapeutics
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 25, 2026, 8:53 AM EDT